BioMedNewsBreaks – MetAlert Inc.’s (MLRT) Acquisition Target’s SafetyNet(R) Featured in New Article

MetAlert (OTC: MLRT), a leading solution provider for consumers/patients afflicted with movement, cognitive and spatial awareness disorders, recently announced that it offered $4.5 million in a cash and stock deal to acquire TrakTec LLC. Offering affordable, scalable location-awareness technology solutions, TrakTec made the news in a new Fairmont Post article that discusses its SafetyNet(R) service and others like it that are providing peace of mind for caregivers and loved ones and helping to quickly locate individuals who may be in danger. “Many police departments in the country have already begun to take advantage of these technologies to locate and rescue missing citizens who have autism, dementia and Alzheimer’s. Just a few days ago, the Chelmsford Police Department reported that they located a missing woman using a tracking system called the ‘SafetyNet(R) System,’” the article reads. “The SafetyNet is intended to assist in the faster identification of missing people with cognitive impairments that have a tendency to get lost or disoriented. Police departments provide qualified participants a SafetyNet bracelet to wear around their wrist or ankle at all times. The bracelet has a radio frequency transmitter that transmits a continuous signal that may be used to pinpoint the user’s specific position if they go missing. In some cases, SafetyNet’s radio frequency technology has been proven to be more successful than GPS or cellular, particularly in tough environments such as thickly forested regions, buildings, basements, and shallow water.”

To view the full article, visit https://ibn.fm/XBI0r

About MetAlert Inc.

MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, selling and licensing products, services and intellectual property in the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring sectors. With over 20 years of experience and an extensive patent portfolio, MetAlert is a leading solution provider for consumers/patients afflicted with movement, cognitive and spatial awareness disorders. This market represents approximately 2.9% of the world’s population. The company offers global end-to-end hardware, software and connectivity solutions, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products, enterprise and government agency applications. Utilizing the latest in miniaturized, low power consumption GPS, cellular, RF, NFC, and BLE technologies, caregivers are enabled to track and monitor patients in real time. The company is known for its game-changing and award-winning patented GPS SmartSole(R) — think Dr. Scholl’s meets LoJack, the world’s first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based business model is built around technology innovation with intellectual property protection. The company has international distributors servicing customers around the globe with subscribers in over 40 countries. MetAlert is a U.S. military government contractor and has other customers that include public health authorities, municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information, visit the company’s website at www.MetAlert.com.

NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) Featured in MarketScreener Editorial on Targeted AI Applications

Izotropic (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3), a medical device company advancing imaging-based products for…

4 hours ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) Reports 51% Revenue Growth, Strong Cash Position to Advance AVERSA Fentanyl

Nutriband (NASDAQ: NTRB) reported financial results for the six months ended July 31, 2025, highlighted…

1 day ago

BioMedNewsBreaks — Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Engages IBN to Lead Corporate Communications

Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy and targeted treatments for…

1 day ago

BioMedNewsBreaks — Lantern Pharma (NASDAQ: LTRN) CEO Panna Sharma Featured on IBN’s BioMedWire Podcast 

Lantern Pharma (NASDAQ: LTRN), an AI-driven oncology company developing targeted cancer therapies with its proprietary…

1 day ago

BioMedNewsBreaks — Clene Inc. (NASDAQ: CLNN) Advances Toward NDA Submission for ALS Therapy

Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company…

2 days ago

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Signs Deal with Worldwide Leader in Specialized Diagnostics 

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced a Research License and…

2 days ago